USANA lowers guidance
This article was originally published in The Tan Sheet
Executive Summary
The direct-seller of nutritional, personal care and weight management products projects 2009 net sales of $390 million to $400 million, a 7 to 9 percent decrease from its 2008 revenues. USANA Health Sciences in February projected a 6 to 8 percent reduction in net sales for the year, accounting for foreign exchange losses. In its 2009 first quarter, the Salt Lake City-based company said April 28 it saw global net sales fall 4.2 percent to $97.3 million and North American revenues dropped 10.2 percent to $55.9 million. Though the firm pinned its declines largely on the negative impact of currency changes, net sales in North America were off by 2.2 percent excluding currency exchange for the three months ended April 4. CEO Dave Wentz expects the firm's associate ranks to grow and noted that the number of active North American associates grew slightly, 2.1 percent, over the year-ago quarter to 97,000
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.